

Pyridazinediones and amino acid receptors: theoretical studies, design, synthesis, and evaluation of novel analogues

[Jeremy R Greenwood](#)

A thesis submitted for the degree of Doctor of Philosophy

The Department of Pharmacology, The University of Sydney, March 1999

Contents

<u>Contents</u>	2
<u>Opening remarks</u>	13
<u>Declaration</u>	14
<u>Acknowledgements</u>	15

Text

<u>1. Introduction</u>	18
<u>1.1 Preamble</u>	18
<u>1.2 Guide to chapters</u>	19
<u>1.3 Key references</u>	21
<u>2. Tautomerism of hydroxy-pyridazines: the N-oxides</u>	24
<u>2.1 Introduction</u>	25
<u>2.2 Methods and results</u>	27
<u>2.3 Discussion</u>	32
<u>2.4 Conclusion</u>	36
<u>2.5 Calculation details</u>	37
<u>2.6 Acknowledgments</u>	37
<u>2.7 References</u>	37
<u>3. The tautomerism of pyridazinediones</u>	50
<u>3.1 Introduction</u>	51
<u>3.2 Methods and results</u>	53
<u>3.2.1 Generation of tautomers and conformers</u>	
<u>3.2.2 Discrimination of preferred conformers and low energy tautomers</u>	
<u>3.2.3 Calculation of gas phase geometries</u>	
<u>3.2.4 Calculation of gas phase energies</u>	
<u>3.2.5 Calculation of aqueous phase properties</u>	

<u>3.3 Key to Tables, Charts, Figures and geometries</u>	57
<u>3.4 Discussion</u>	58
<u>3.4.1 Conformation</u>	
<u>3.4.2 Structure determination</u>	
<u>3.4.3 Gas phase tautomerism predictions</u>	
<u>3.4.4 Solvation effects according to different models</u>	
<u>3.4.5 Aqueous phase tautomerism</u>	
<u>3.4.6 <i>Ab initio</i> prediction of relative pK_a</u>	
<u>3.5 Conclusion</u>	66
<u>3.6 Calculation details</u>	67
<u>3.7 References</u>	67
<u>4. Pyridazinediones as candidates for neuroactive amino acid analogues</u>	89
<u>4.1. Brief introduction to GABA receptors</u>	90
<u>4.2. Brief introduction to Excitatory Amino Acid (EAA) receptors</u>	93
<u>4.3. Pyridazinediones as amino acid analogues</u>	97
<u>4.3.1. The resemblance of pyridazinediones to 3-isoxazolols</u>	
<u>4.3.2. Choosing to investigate maleic hydrazide derivatives</u>	
<u>4.3.3. The role of tautomerism</u>	
<u>4.3.4. The target series</u>	
<u>4.4. References</u>	105
<u>5. Synthesis of pyridazinedione amino acid analogues</u>	116
<u>5.1 Analogues of muscimol (5-aminomethyl-3-isoxazolol)</u>	118
<u>5.1.1 4-Aminomethylpyridazine-3,6(1,2<i>H</i>)-dione</u>	
<u>5.1.2 2-Methyl-4-aminomethyl-6-hydroxypyridazin-3(2<i>H</i>)-one</u>	
<u>5.1.3 2-Methyl-5-aminomethyl-6-hydroxypyridazin-3(2<i>H</i>)-one</u>	

<u>5.2 Analogues of THIP (4,5,6,7-tetrahydroisoxazolo[5,4-c]pyridine-3-ol)</u>	128
<u>5.2.1 5,6,7,8-Tetrahydropyrido[3,4-d]pyridazine-1,4(2,3<i>H</i>)-dione</u>	
<u>5.2.2 1-Hydroxy-3-methyl-5,6,7,8-tetrahydropyrido[3,4-d]pyridazin-4(3<i>H</i>)-one</u>	
<u>5.2.3 2-Methyl-4-hydroxy-5,6,7,8-tetrahydropyrido[3,4-d]pyridazin-1(2<i>H</i>)-one</u>	
<u>5.3 AMPA / HIBO analogues</u>	132
<u>5.3.1 2-Amino-3-(pyridazine-3,6(1,2<i>H</i>)-dion-4-yl)propanoic acid</u>	
<u>5.3.2 2-Amino-3-(2-methyl-6-hydroxypyridazin-3(2<i>H</i>)-on-4-yl)propanoic acid</u>	
<u>5.3.3 2-Amino-3-(2-methyl-6-hydroxypyridazin-3(2<i>H</i>)-on-5-yl)propanoic acid</u>	
<u>5.3.4 2-Amino-3-(6-hydroxypyridazin-3(2<i>H</i>)-on-2-yl)propanoic acid</u>	
<u>5.4 AMAA / ibotenic acid analogues</u>	139
<u>5.4.1 Pyridazine glycines via ring nucleophilic substitution</u>	
<u>5.4.2 Glycino pyridazinones via pyridazine aldehydes</u>	
<u>5.4.3 Glycino pyridazinones via ethyl 2-(pyridazinyl)acetates</u>	
<u>5.5 Conclusion</u>	146
<u>5.6 Experimental</u>	147
<u>5.7 Acknowledgments</u>	170
<u>5.8 References</u>	170
<u>6. Theoretical studies on the free-radical bromination of methyl-pyridazines</u>	172
<u>6.1 Introduction</u>	173
<u>6.2 Method</u>	174
<u>6.3 Results</u>	175
<u>6.4 Discussion</u>	176
<u>6.5 Experimental</u>	178
<u>6.6 Calculation Details</u>	179
<u>6.7 Conclusion</u>	180

<u>6.8 Acknowledgments</u>	180
<u>6.9 References</u>	181
<u>7. Pharmacological screening <i>in vitro</i></u>	191
<u>7.1 GABA_A activity: Guinea-pig isolated ileum preparation</u>	192
<u>7.1.1 Results</u>	
<u>7.1.2 Discussion</u>	
<u>7.1.3 Experimental</u>	
<u>7.2 EAA activity: Cortical wedge preparation</u>	195
<u>7.2.1 Results</u>	
<u>7.2.2 Discussion</u>	
<u>7.2.3 Experimental</u>	
<u>7.3 GABA_C activity</u>	198
<u>7.4 Conclusion</u>	199
<u>7.5 Acknowledgments</u>	199
<u>7.6 References</u>	199
<u>8. Heterocycles as bioisosteres for the α-carboxylate moiety of glutamate in AMPA receptor agonists: A review and theoretical study</u>	209
<u>8.1 Introduction</u>	211
<u>8.1.1 Carboxylate bioisosterism and drug design</u>	
<u>8.1.2 EAA and AMPA receptors</u>	
<u>8.1.3 Alanino heterocycles active at AMPA receptors</u>	
<u>8.1.4 The theoretical study of heterocycles related to AMPA receptors</u>	
<u>8.2 Methods and results</u>	214
<u>8.2.1 Choice of model compounds</u>	
<u>8.2.2 Structure determination</u>	

8.2.3 Gas phase thermochemistry and tautomerism	
8.2.4 Point charges and dipoles	
8.2.5 Aqueous phase modelling and tautomerism	
8.2.6 pK_a estimation	
8.3 Key to tables, graphs, charts and figures	219
8.4 Discussion	222
8.4.1 Tautomerism	
8.4.2 pK_a behaviour	
8.4.3 Observations on the requirements for carboxylate bioisosterism at the AMPA receptor	
8.5 Conclusion	234
8.6 Calculation details	235
8.7 Acknowledgments	235
8.8 References	236

Tables

[Chapter 2.](#)

Table 2.1 Hydroxy conformers	40
Table 2.2 All tautomers at HF/6-31G(d)	40
Table 2.3 Compound energies and free energies at 298.15K	41
Table 2.4 Higher level calculations on 4-hydroxy-pyridazine 1-oxide	42
Table 2.5 Free energies of solvation	43
Table 2.6 Tautomer ratios in solution	44
Table 2.7 Relative acidities	44
Table 2.8 Literature pK _a values	45

[Chapter 3.](#)

Table 3.1 Unfavourable conformers	70
Table 3.2 Gas phase tautomer energies	72

Table 3.3 Effect of large basis set optimisation on 3	74
Table 3.4 Comparison of 2h with X-ray structure	75
Table 3.5 Comparison of 3b with X-ray structures	75
Table 3.6 Free energies of solvation	76
Table 3.7 Estimated tautomer ratios	78
Table 3.8 Equilibrium free energies and pK _a	79
Table 3.9 Experimental pK _a s	80
Chapter 4.	
Table 4.1 Target series	103
Chapter 6.	
Table 6.1 Experimental products	182
Table 6.2 Relative and absolute energies	185
Table 6.3 Heats of reaction	186
Chapter 8.	
Table 8.1 Summary of AMPA analogue activities	241
Table 8.2 Energies and tautomerism of model heterocycles	245
Table 8.3 Solvation energies, pK _a predictions and literature values	248
Figures and traces	
Chapter 2.	
Figure 2.1 pyridazine 1,2-dioxide	45
Figure 2.2 3-hydroxypyridazine 1-oxide	46
Figure 2.3 4-hydroxypyridazine 1-oxide	46
Figure 2.4 5-hydroxypyridazine 1-oxide	47
Figure 2.5 6-hydroxypyridazine 1-oxide	47
Chapter 3.	
Figure 3.1 Summary of tautomeric behaviour	57

[Figure 3.2](#) Formal structures of [3c](#), [3f](#), and [3f](#) 60

[Figure 3.3](#) Resonance of [2-b](#) 66

[Chapter 4.](#)

[Figure 4.1](#) maleic hydrazide 99

[Figure 4.2](#) 3-hydroxy pyridazine 1-oxide 99

[Figure 4.3](#) 4,5-dimethyl-3-isoxazolol 99

[Figure 4.4](#) Overlay: 3, 17a 107

[Figure 4.5](#) Overlay: 4, 17b 108

[Figure 4.6](#) Overlay: 5, 18a 109

[Figure 4.7](#) Overlay: 6, 18b 110

[Figure 4.8](#) Overlay: 13, 19a 111

[Figure 4.9](#) Overlay: 14, 19b 112

[Figure 4.10](#) Overlay: 15, 20a 113

[Figure 4.11](#) Overlay: 11, 20b 114

[Chapter 6.](#)

[Figure 6.1](#) Image and PM3 energies of [9\(2\)](#), [9\(4\)](#), [10\(2\)](#), [10\(5\)](#) 187

[Figure 6.2](#) Wavefunction map of HOMO of [9\(2\)](#), [9\(4\)](#), [10\(2\)](#), [10\(5\)](#) 188

[Chapter 7.](#)

[Trace 7.1](#) 1 followed by GABA 201

[Trace 7.2](#) 2 followed by GABA 201

[Trace 7.3](#) 3 followed by GABA 201

[Trace 7.4](#) 5 followed by GABA 201

[Trace 7.5](#) 6 followed by GABA 202

[Trace 7.6](#) 7 followed by GABA 202

[Trace 7.7](#) GABA followed by TACA 202

[Trace 7.8](#) 9 203

[Trace 7.9](#) CPP plus 9 203

[Trace 7.10](#) CNQX plus 9 203

Trace 7.11 10	204
Trace 7.12 CPP plus 10	204
Trace 7.13 CNQX plus 10	205

Chapter 8.

Figures 8.1.26 to 8.1.38 Conjugate base anions of model acidic heterocycles, CPK rendering, point charge distributions	250
Figures 8.2.26 to 8.2.38 Conjugate base anions of model acidic heterocycles, Van der Waals surfaces, electrostatic potentials	252
Figure 8.3 Conjugate base anions 26- to 33- overlaid	254
Figure 8.4 1-methyl uracil anion, methyl guanidinium cation, and methanol complex	254
Figure 8.5 4,5-dimethyl-3-isoxazolol anion, methyl-guanidinium cation, water, and methanol complex	254

Charts and Schemes

Chapter 1.

Scheme 1.1 maleic hydrazide	18
Scheme 1.2 important amino acids	19

Chapter 2.

Chart 2.1 structures referred to in text	48
--	----

Chapter 3.

Chart 3.1 3,4-substituted structures, 1	82
Chart 3.2 3,5-substituted structures, 2	83
Chart 3.3 3,6-substituted structures, 3	84
Chart 3.4 4,5-substituted structures, 4	85
Chart 3.5 related structures	86

Chapter 4.

Scheme 4.1 Some compounds acting at the GABA receptor	90
Scheme 4.2 3-isoxazolols with varying activity at GABA receptors	92
Scheme 4.3 Two endogenous excitatory amino acids	93
Scheme 4.4 Agonists which have been used to characterise ionotropic EAA receptor subtypes	95
Scheme 4.5 isoxazole α -amino acids with varying activity at EAA receptors, and the amino acid willardiine	97

Chapter 5.

Scheme 5.1 Synthesis of 4-aminomethylpyridazine-3,6(1,2 <i>H</i>)-dione 7	118
Scheme 5.2 Synthesis of 2-methyl-4-aminomethyl-6-hydroxypyridazin-3(2 <i>H</i>)-one 15	121
Scheme 5.3 Synthesis of 2-methyl-5-aminomethyl-6-hydroxypyridazin-3(2 <i>H</i>)-one 20	124
Scheme 5.4 Synthesis of 5,6,7,8-Tetrahydropyrido[3,4- <i>d</i>]pyridazine-1,4(2,3 <i>H</i>)-dione 25	128
Scheme 5.5 Synthesis of 1-hydroxy-3-methyl-5,6,7,8-tetrahydropyrido[3,4- <i>d</i>]pyridazin-4(3 <i>H</i>)-one 30	130
Scheme 5.6 Synthesis of 2-Amino-3-(pyridazine-3,6(1,2 <i>H</i>)-dion-4-yl)propanoic acid 33	132
Scheme 5.7 Synthesis of 2-amino-3-(2-methyl-6-hydroxypyridazin-3(2 <i>H</i>)-on-4-yl)propanoic acid 35	134
Scheme 5.8 Synthesis of 2-amino-3-(2-methyl-6-hydroxypyridazin-3(2 <i>H</i>)-on-5-yl)propanoic acid 37	135
Scheme 5.9 Synthesis of 2-amino-3-(6-hydroxypyridazin-3(2 <i>H</i>)-on-2-yl)propanoic acid 43	136
Scheme 5.10 Chloropyridazines synthesised as starting materials for ring nucleophilic substitution	140
Scheme 5.11 Failure of Modified Sørensen Reaction on ring halogen	141
Scheme 5.12 Synthesis of a pyridazinyl aldehyde 49 but failure of α -amino acid	

syntheses	142
Scheme 5.13 Synthesis of an ethyl 2-(dimethoxypyridazinyl)acetate 53 , and its oxime and bromide, but failure of synthesis of the glycino pyridazinone 58	144
Chapter 6.	
Scheme 6.1 Mechanism of the Wohl-Zeigler reaction	173
Chapter 7.	
Chart 7.1 muscimol, THIP, and GABA analogues tested	206
Chart 7.2 AMPA, AMAA, and glutamate analogues tested	207
Chart 7.3 other analogues referred to	208
Chapter 8.	
Chart 8.1 Structures with moderate to high potency	255
Chart 8.2 Structures with reduced or abolished potency	256
Chart 8.3 Model des-glycino heterocyclic conjugate base anions	257
Chart 8.4 Tautomerism of model heterocycles	258
Chart 8.5 Tridentate binding models at AMPA receptors	259
Chart 8.6 Tridentate binding to two putative residues, with and without water mediation	260
Graphs	
Chapter 7.	
Graph 7.1 log[Dose] - response curves for 9 and 10 , compared with AMPA and NMDA	196
Chapter 8.	
Graph 8.1 Experimental pK _a s vs. <i>ab initio</i> predictions	261
Graph 8.2 Experimental pK _a s vs. empirical predictions	261
Graph 8.3 pK _a s: <i>ab initio</i> vs. empirical predictions	262

Molecules

Indices of optimised geometries (.pdb format)

Chapter 2	49
Chapter 3	86
Chapter 4	115
Chapter 6	189
Chapter 8	216

Opening remarks

NOTE: The hard copy you are reading is for archival purposes only, and does not contain all of the information in the thesis. It has been printed from the hypertext to meet faculty requirements. Please use the hypertext version.

In 1998, the University of Sydney Academic Board (AB 11.3.98) made provision for the electronic submission of PhD theses. This thesis is presented in hypertext format, primarily because of the advantage of being able to include various resources, such as interactive three dimensional molecular data and multiple colour images, impossible within traditional media. Other advantages include rapid and cheap dissemination and the preservation of numerical data in a readily useable form. Effort has been made to make the work as general and standard for long-term accessibility as possible. The interface is designed to be simple and self-explanatory. The thesis is world readable via the web server

<http://gabacus.pharmacol.usyd.edu.au/thesis> and will be cut onto CD-ROM plus hard copy of the text for storage by the university. While it is possible to print the text, the work is intended to be read electronically.

[Chapters 2, 3, 6](#) and [8](#) have previously been published through electronic conferences, and also via the print journal J. Molecular Structure (Theochem), or the electronic [Internet Journal of Chemistry](#). Most of the other material has been presented through conference posters and talks.

Links to all required software for browsing on various platforms are included in the [software directory](#) to assist archival. The text is presented in Hypertext Markup Language (.htm) and is designed to be browsed using any standard web browser on any platform, [Netscape 2.x](#) or higher, [Internet Explorer 3.x](#) or higher. Images are in standard formats (.jpg, .gif). Molecules are presented mostly as Cambridge Protein Data Bank (.pdb) format, some are offered in an alternative X-Mol cartesian coordinates (.xyz) format. In order to view molecular structures, a viewer such as [Rasmol](#) or preferably the browser plugin [MDL's Chemscape Chime](#) should be installed (see the [software directory](#) for a copy). In some instances, use has been

made of the Chime format <embed> tag to call molecular data within the text or tables.

The [search](#) facility included with the thesis is a PERL script which requires that it be served from an appropriately configured web server; this feature may not operate from an archival copy on an isolated machine. The MIME types associated with interactive molecules may also require client and server configuration in order for them to be recognised by a molecular browser should the thesis be mounted on a new site, however the numerical data will still remain readable. While these features of the thesis may become more difficult to access from an archival copy, they are over and above those available in hard copy.

Declaration

The work presented in this thesis is the original work of the author, except where acknowledgment has been made to results supplied by co-workers or previously published. The work was carried out at the Adrien Albert Laboratory of Medicinal Chemistry and Biomolecular Computer Graphics Facility, Department of Pharmacology, University of Sydney, and has not been previously submitted for a degree at any institution.

[Jeremy R Greenwood](#)

Acknowledgments

This *magnum opus* would never have been possible without the generous and long-term support of so many people.

First and foremost, I'd like to thank my supervisors: [Robin Allan](#), [Hugh Capper](#), and [Graham Johnston](#). They provided for my every need: financial, material, and intellectual support - I could not have asked for more. Special thanks over and above and beyond goes to Hugh Capper, companion and friend through long shared hours of coding. And to [Malcolm Gillies](#) for helping to bring me to this point and to whom I owe much of what I know and who installed systems which were vital to the production of this thesis. To my Adrien Albert laboratory co-workers: [Ken Mewett](#), the finest organic chemist I have worked with, an unsung hero, a virtuoso, to whom I am greatly indebted for so much support and advice with chemistry. To [Hue Tran](#), a careful and scrupulous scientist, companion through long hours of synthesis and of much assistance with chemistry and pharmacology. And [Rujee Duke](#), a fine chemist with whom I have enjoyed many a collaboration and conversation. To [Graziano Vaccarella](#): collaborator, co-author, assistant - congratulations on finishing!

And also to the man I have not known, but often cited, the late [Adrien Albert](#) who gave his name to [our lab](#) and devoted his life to the science of heterocycles which I have pursued.

To my mentors at ANU: [Leo Radom](#) and [Ming Wah Wong \(Richard\)](#). With the passing of the years I realise how fortunate I was to have learnt so much in such a short time, and from their inspiration develop a passion for applied quantum chemistry.

To the team at the Royal Danish School of Pharmacy, especially [Povl Krosgaard-Larsen](#) and [Tommy Liljefors](#), whose research has also been an inspiration and whom I'll soon join.

To the men and women who sorted every logistical detail and difficulty, especially [Virginia Fascioli](#) who could always be relied on to pull the rabbit out of the hat just when it was needed. To [Keith Rippon](#) and [Norm Oetsch](#) - magicians with machines of all kinds.

To the computer support teams: [Ben Simons](#), [Geoff Horne](#), and the others who've been at the [NSWCPC](#) to make this project possible. To [Doug Scoullar](#) and [Andy Winter](#) from Architecture for their many rescues and advices. To [Hristo Nikolov](#) and [John Dodson](#) for running a tight ship, prompt support, and an excellent network.

To [Mary Collins](#), collaborator and delicious falafel maker, and her husband [Brad](#) and his collection of the finest Belgian beers - my sanity is due in part to you. Also helping me to stay sane, especially after hours at the Grandstand, friends and colleagues [Jim Delikatny](#), [Harry Wilson](#), [Ian Spence](#), [Slade Mathews](#), [Hilary Lloyd](#), [Peter Burden](#), [Jane Hanrahan](#), [Macdonald Christie](#), [Rachael Jones](#), and [Pat Groenstein](#), among others. And for reminding me of my insanity: [Suzanne Habjan](#) - we worked hard, had fun and enjoyed many wonderful dinners. To the people I've taught with, particularly [Izabela Brzuszcak](#), it was highly rewarding. To [Ann Mitrovic](#), for her unending patience with everyone, especially my brief stint with rat brain slices, and without whom I could not have tested my compounds. To [Jill Maddison](#) and the [Australian Veterinary Association](#) for providing me with both an income and the .htm experience to produce this thesis.

To the [coke](#) machine down the hall for providing my two most crucial synthetic starting materials: caffeine and sucrose.

To my family and the special women and men who have supported me financially, physically, and emotionally: My mother [Janet Paterson](#) who has been through it all and understands, and moreover has provided me a roof to sleep under for much of the duration. My grandmother **Jean Paterson** who also understands, and has provided for me generously. My father [Tony](#). My brother [Philip](#) for many a midnight swim and much good company. And to my special friends: [Camille](#) and

Anna Shanahan, [Tim Booth](#), Jo Lobb, Kevin Brigden, [David Chisholm](#), [Manuela Crank](#), [Margaret Mayhew](#), [Jeremy Lawrence](#), [Margaret Nicholson](#), Jolyon Campbell *requiescat in pace*, [Angela Dean](#), and above all, to [Justine Arnot](#). "Justine, here's a kiss... I'm saving you to end this list".

To all of these people and the many I've neglected to mention, I am grateful and owe a great debt. We've had fun and we've done some science.

[Jeremy R Greenwood](#)